Clinical Trials

NCT IdNCT04107961
TitleA Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)
ConditionPost-kala-azar Dermal Leishmaniasis
OrganizationUniversity of York
Sponsor/CollaboratorsUniversity of York
StatusNot yet recruiting
Location (with distance)
DescriptionThe LEISH3 trial is a randomised, controlled, double blind Phase II clinical trial to evaluate the safety and efficacy of vaccination with ChAd63-KH in the prevention of post-kala azar dermal leishmaniasis (PKDL) in Sudanese visceral leishmaniasis (VL) patients previously treated with sodium stibogluconate / paromomycin (SSG / PM).